-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Ignyte Acquisition (NASDAQ:IGNY) and Inhibikase Therapeutics (NYSE:IKT)
Analyzing Ignyte Acquisition (NASDAQ:IGNY) and Inhibikase Therapeutics (NYSE:IKT)
Ignyte Acquisition (NASDAQ:IGNY – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Earnings & Valuation
This table compares Ignyte Acquisition and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.
Get Ignyte Acquisition alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ignyte Acquisition | N/A | N/A | -$490,000.00 | N/A | N/A |
| Inhibikase Therapeutics | $3.10 million | 7.36 | -$14.79 million | ($0.74) | -1.22 |
Ignyte Acquisition has higher earnings, but lower revenue than Inhibikase Therapeutics.
Insider and Institutional Ownership
61.1% of Ignyte Acquisition shares are owned by institutional investors. Comparatively, 13.3% of Inhibikase Therapeutics shares are owned by institutional investors. 55.8% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.Risk & Volatility
Ignyte Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Ignyte Acquisition and Inhibikase Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ignyte Acquisition | 0 | 0 | 0 | 0 | N/A |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Ignyte Acquisition and Inhibikase Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ignyte Acquisition | N/A | 365.46% | -0.83% |
| Inhibikase Therapeutics | -4,894.27% | -48.78% | -44.49% |
Summary
Ignyte Acquisition beats Inhibikase Therapeutics on 5 of the 8 factors compared between the two stocks.
About Ignyte Acquisition
(Get Rating)
Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
About Inhibikase Therapeutics
(Get Rating)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Ignyte Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyte Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Ignyte Acquisition (NASDAQ:IGNY – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
纳斯达克收购(纳斯达克代码：IGNY-GET)和Inhibikase治疗公司(纽约证券交易所代码：IKT-GET评级)都是小盘医疗公司，但哪一家更好？我们将根据风险的强弱、分析师的建议、收益、股息、盈利能力、机构所有权和估值对这两家公司进行比较。
Earnings & Valuation
收益与估值
This table compares Ignyte Acquisition and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.
下表比较了Ignyte收购和Inhibikase治疗公司的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ignyte Acquisition | N/A | N/A | -$490,000.00 | N/A | N/A |
| Inhibikase Therapeutics | $3.10 million | 7.36 | -$14.79 million | ($0.74) | -1.22 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Ignyte收购 | 不适用 | 不适用 | -$490,000.00 | 不适用 | 不适用 |
| 抑制酶疗法 | 310万美元 | 7.36 | -1,479万元 | ($0.74) | -1.22 |
Ignyte Acquisition has higher earnings, but lower revenue than Inhibikase Therapeutics.
与Inhibikase治疗公司相比，Ignyte收购的收益更高，但收入更低。
Insider and Institutional Ownership
内部人与机构持股
Risk & Volatility
风险与波动性
Ignyte Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Ignyte收购的贝塔系数为0.01，表明其股价的波动性比标准普尔500指数低99%。相比之下，Inhibikase Treeutics的贝塔系数为1.19，这表明其股价的波动性比标准普尔500指数高出19%。
Analyst Ratings
分析师评级
This is a summary of recent recommendations and price targets for Ignyte Acquisition and Inhibikase Therapeutics, as provided by MarketBeat.com.
这是MarketBeat.com提供的Ignyte收购和Inhibikase治疗公司最近的建议和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ignyte Acquisition | 0 | 0 | 0 | 0 | N/A |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Ignyte收购 | 0 | 0 | 0 | 0 | 不适用 |
| 抑制酶疗法 | 0 | 0 | 0 | 0 | 不适用 |
Profitability
盈利能力
This table compares Ignyte Acquisition and Inhibikase Therapeutics' net margins, return on equity and return on assets.
下表比较了Ignyte收购和Inhibikase治疗公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Ignyte Acquisition | N/A | 365.46% | -0.83% |
| Inhibikase Therapeutics | -4,894.27% | -48.78% | -44.49% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Ignyte收购 | 不适用 | 365.46% | -0.83% |
| 抑制酶疗法 | -4,894.27% | -48.78% | -44.49% |
Summary
摘要
Ignyte Acquisition beats Inhibikase Therapeutics on 5 of the 8 factors compared between the two stocks.
与两只股票相比，Ignyte收购在8个因素中有5个超过了Inhibikase治疗公司。
About Ignyte Acquisition
关于Ignyte收购
(Get Rating)
(获取评级)
Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
Ignyte Acquisition Corp.没有重大业务。拟与一家或多家企业进行合并、换股、资产收购、股票购买、资本重组、重组或其他类似的业务合并。该公司打算专注于生命科学、生物技术和医疗保健领域的目标业务。Ignyte Acquisition Corp.成立于2020年，总部设在纽约。
About Inhibikase Therapeutics
关于Inhibikase疗法
(Get Rating)
(获取评级)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
临床阶段制药公司Inhibikase Treateutics，Inhibikase Treeutics，Inhibikase Treateutics，Inhibikase Treateutics，Inc.是一家临床阶段制药公司，开发帕金森氏病(PD)和大脑内外相关疾病的疗法。该公司的候选产品包括用于治疗帕金森氏症以及帕金森氏症早期症状(如吞咽、吞咽困难、神经原性便秘和多系统萎缩)的小分子阿贝尔森酪氨酸激酶抑制剂IKT-148009；以及抗癌药物伊马替尼的前药IKT-001Pro，该药物正处于临床前开发阶段，旨在将胃肠道副作用降至最低，并用于治疗血液和胃癌。它还参与开发其他神经疾病的各种研究计划。该公司与约翰·霍普金斯大学、亚利桑那州立大学、密歇根州立大学以及路易斯安那州立大学有研发合作。Inhibikase治疗公司成立于2008年，总部设在佐治亚州亚特兰大。
Receive News & Ratings for Ignyte Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyte Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ignyte收购日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ignyte收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧